The Impact of Body Weight on Clinical and Immunological Outcomes in Relapse-Remitting Multiple Sclerosis Patients

NCT05735067 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2023-12-19

No results posted yet for this study

Summary

Our study aimed to investigate the effect of interferon beta 1a on the clinical and immunological parameters in Egyptian relapse-remitting multiple sclerosis patients

Conditions

Interventions

OTHER

Blood sample collection

5 ml of blood samples were withdrawn from RRMS patients

Sponsors & Collaborators

  • German University in Cairo

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2023-05-01
Completion
2025-07-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05735067 on ClinicalTrials.gov